Dennis Walsh - Deciphera Pharmaceuticals Independent Director
| DCPH Stock | USD 25.27 0.01 0.04% |
Director
Mr. Dennis L. Walsh is Independent Director of the Company. Mr. Walsh is currently Senior Vice President and Chief Financial Officer of Americo Life, Inc., a privately owned life insurance company, a role he has held since October 2018. Prior to Americo, Mr. Walsh was a partner with Walsh Washburn, LLC, a tax and finance consulting firm, which he cofounded in 2003. Prior to founding Walsh Washburn, LLC, Mr. Walsh was the controller and tax director for six years for Americo Life, Inc. Mr. Walsh began his career with Touche Ross Company, where he served in the tax department for ten years since 2015.
| Age | 50 |
| Tenure | 9 years |
| Address | 200 Smith Street, Waltham, MA, United States, 02451 |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Dennis Walsh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dennis Walsh against Deciphera Pharmaceuticals stock is an integral part of due diligence when investing in Deciphera Pharmaceuticals. Dennis Walsh insider activity provides valuable insight into whether Deciphera Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Deciphera Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Deciphera Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dennis Walsh over six months ago Acquisition by Dennis Walsh of 30000 shares of Deciphera Pharmaceuticals subject to Rule 16b-3 | ||
Dennis Walsh over six months ago Purchase by Dennis Walsh of 11000 shares of Deciphera Pharmaceuticals |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5629) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.43. The current Return On Capital Employed is estimated to decrease to -0.59. As of now, Deciphera Pharmaceuticals' Fixed Asset Turnover is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Asset Turnover is estimated to increase to 0.36, while Total Assets are projected to decrease to under 393.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Jenness | Prestige Brand Holdings | 73 | |
| Thomas Penn | ANI Pharmaceuticals | 72 | |
| David Hirsch | Collegium Pharmaceutical | 47 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Lawrence Olanoff | Ironwood Pharmaceuticals | 66 | |
| Stephen Shohet | Amphastar P | 82 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Jon Duane | Ironwood Pharmaceuticals | 59 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Sam Gejdenson | Phibro Animal Health | 70 | |
| John Byom | Prestige Brand Holdings | 66 | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Richard Prins | Amphastar P | 61 | |
| David Nash | ANI Pharmaceuticals | 62 | |
| Charles Hinkaty | Prestige Brand Holdings | 64 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Francis Fildes | Avadel Pharmaceuticals PLC | 71 | |
| Guillaume Cerutti | Avadel Pharmaceuticals PLC | 49 | |
| Catherine Moukheibir | Ironwood Pharmaceuticals | 58 | |
| Georges Gemayel | Supernus Pharmaceuticals | 58 | |
| Tracy Marshbanks | ANI Pharmaceuticals | 52 | |
Management Performance
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.28 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Ruddy, VP Officer | ||
| John Martin, Independent Director | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Patricia Allen, Independent Director | ||
| Thomas Kelly, CFO | ||
| Susan Kelley, Director | ||
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Liam Ratcliffe, Independent Director | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Kevin Brodbeck, Senior Officer | ||
| Christopher Morl, Chief Business Officer | ||
| Oliver Rosen, Chief Medical Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Michael Taylor, President CEO, Director | ||
| Melissa Forst, IR Contact Officer | ||
| James Bristol, Independent Director | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Edward Benz, Independent Director | ||
| Thomas JD, CFO VP | ||
| Dennis Walsh, Independent Director | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory | ||
| Michael Ross, Independent Director |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 1.8 B | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 30.02 % | ||||
| Shares Owned By Institutions | 72.31 % | ||||
| Number Of Shares Shorted | 5.75 M | ||||
| Price To Earning | (6.78) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Deciphera Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Deciphera Pharmaceuticals' short interest history, or implied volatility extrapolated from Deciphera Pharmaceuticals options trading.
Pair Trading with Deciphera Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Deciphera Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Deciphera Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Deciphera Stock
| 0.46 | EVO | Evotec SE ADR | PairCorr |
The ability to find closely correlated positions to Deciphera Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Deciphera Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Deciphera Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Deciphera Pharmaceuticals LLC to buy it.
The correlation of Deciphera Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Deciphera Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Deciphera Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Deciphera Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Deciphera Pharmaceuticals LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Deciphera Stock analysis
When running Deciphera Pharmaceuticals' price analysis, check to measure Deciphera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Deciphera Pharmaceuticals is operating at the current time. Most of Deciphera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Deciphera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Deciphera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Deciphera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Deciphera Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.29) | Revenue Per Share 1.92 | Quarterly Revenue Growth 0.329 | Return On Assets (0.28) | Return On Equity (0.56) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.